MelodyVR rises on Live Nation partnership for virtual reality gigs – Proactive Investors UK

MelodyVR Group PLC (LON:MVR) was an early riser on Wednesday, advancing 14% to 5.12p, on the back of an exclusive partnership with Live Nation UK.

The two firms will organise a series of new live concerts connecting artists and fans in virtual reality, using the AIM-listed firms technology.

Fans will have the choice of watching performances set in Londons O2 Academy Brixton from multiple points, including on stage with the artists themselves.

Talking about partnerships, () rose 5% to 8.5p after extending its contract with grocery giant Asda by two years.

The partnership includes the management of warehousing and national transport operations across four sites in Doncaster, Larne, Rochdale and Wigan, covering frozen, chilled and ambient grocery as well as general merchandise.

The logistics firm has been working with Asda since 2005.

() said it has signed a services contract with Greencastle Capital to manage the JOE media business, which has been bought out of administration following its collapse in May. The media technology firm said under the terms of the deal it will immediately manage all operational and commercial aspects of the JOE media businesses in the UK and Ireland following regulatory clearance. In return, the company will be paid a monthly fee of 50,000 as well as 25% of all profits if certain targets are met. JOE media is the largest independent digital media company in the Republic of Ireland and has been one of the fastest growing media companies in the UK since it launched in 2015. The brand is well known for its House of Rugby series, the most-watched rugby show in the world, and generated over 10mln in revenue in 2019.

() has told investors that its desktop review of the wholly-owned Annaburroo gold project in Australias Northern Territoryhas identified potential for further delineation of gold mineralisation. It noted that the project remains underexplored with more than 95% of the area remaining unsampled and untested. The central and western portions of the licence are completely untested, the companyadded, and moreover its review concluded that prior exploration in certain areas are not considered effective due to thick transported soil cover which has potentially masked mineralisation.

() has signed a clinical and commercial licensing deal with a company developing a gene silencing drug for solid tumours. Under the agreement, APEIRON Biologics will be allowed to use the AIM-listed groups Flow Electroporation technology and ExPERT platform to advance APN401, a siRNA-based cell therapy. In return, MaxCyte will receive undisclosed development and approval milestones and sales-based payments in addition to other licensing fees.

() has told investors its full underground development team is now back at work and blasting operations have resumed at the Cononish gold and silver minein Scotland. The return to full operation was in line with the group's schedule announced in June, and operations are in full compliance with the coronavirus (COVID-19) safe operating procedures, the company added. At the same time, Scotgoldis ramping up drilling capacity at the mine project with the addition of extra rigs, via a new agreement with Epiroc UK & Ireland Ltd.

Holdings PLC () has noted that researchers driving innovation at the cancer diagnostic grouphave contributed "world-class science to the field of rheumatoid arthritis (RA) and its early detection. Thats the opinion of Oncimmunes chief executive, Dr Adam Hill, whose ImmunoINSIGHTS team was integral to a paper published in the journal Arthritis Research & Therapy. Led by Oncimmune's Dr Petra Buddle and Dr Hans-Dieter Zucht, a study was set up to assess the diagnostic potential of IgG antibodies in early RA. It did so by assessing 411 patients enrolled in Germany. The scientists concluded that the autoantibody, cTRA2B-IgG, had the potential to improve diagnosis of early-stage rheumatoid arthritis.

() said it has executed an agreement with IOV Labs Limited to establish a joint venture (JV) in Singapore. The blockchain investment and advisory firm said the JV will promote and commercialise IOVs services and technologies, principally in the Asian markets, and be financed by IOV through a loan which is to be repaid from future revenues. IOV is the parent of RSK, the developers of the first smart contract platform secured by the Bitcoin network in which Coinsilium holds an interest of around 1.9mln RIF tokens. It also owns Taringa!, one of the largest Spanish language social media apps with around 30mln members.

() has said it is expecting the completion of the divestment of the companys legacy oil and gas interest, DT Ultravert, during the next week. The CBD-focused firmalso noted a change in deal terms which both advances the transaction to completion and in the longer-term offers improved value to Zoetic. It has agreed with the acquirer, Path Investments, that Zoetic will receive a higher royalty over future production - increased to 6% from 5% -and it will accept a higher allocation of share warrants, to a total of 30mln. Meanwhile, Path will cover Zoetics professional and technical costs with cash.

e-Therapeutics PLC () has unveiled plans to raise up to 12.4mln to fund its next stage of growth and value creation by expanding its drug discovery platform and asset pipeline. In an announcement after the close on Tuesday, the biopharmaceutical firm said it will raise 6.3mln of the total in a placing through the issue of around 52.8mln new shares at 12p each, a 30% discount to its Tuesday closing price. Meanwhile, the company also announced a subscription to raise around 2.8mln through the issue of 23.3mln new shares at the same price and a broker option to raise another 2.5mln. The group also made a retail offer at the 12p price on the platform to provide certain existing retail shareholders and other retail investors with an opportunity to participate in the fundraise. In an announcement on Wednesday morning, e-Therapeutics said the retail offer had raised 750,000 through the issue of 6.25mln shares.

(LON SUPR), the real estate investment trust providing secure, inflation-protected, long income from grocery property in the UK, said it board has today declared an interim dividend in respect of the period from April 1, 2020, to June 30, 2020, of 1.460p per ordinary share, payable on or around August 7, 2020. The ex-dividend date will be July 16, 2020, with a record date of July 17, 2020. The dividend will be paid 0.818p as a Property Income Distribution in respect of the Company's tax-exempt property rental business and 0.642p as an ordinary UK dividend. The company has now declared four quarterly dividends totalling 5.8p per ordinary share for the financial year ended June 30, 2020, achieving its full-year dividend target.

() has announced the appointment of Zeus as its Nominated Adviser and Joint Broker with immediate effect.

(), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models has said it will be attending and presenting at a series of investor events from July 9 to 1, 2020. Cathal Friel, Open Orphan's chief executive officer, will be in attendance for all of the events and will be presenting to update existing and potential investors on the company's business plans for 2020-2021. No new material information will be disclosed at any of the events, which are: Hardman & Co. Investor Forum Webinar, July 9, 2020, 3.00pm-4.30pm; Proactive Investors One2One Investor Forum, July 9, 2020, 6.00pm-8pm; and Mello Virtual - Investing in the New World, July 11, 2020, 9.00am-5.00pm.

IXICO ), the data analytics company delivering insights in neuroscience, has announced the company's digital attendance at the On Helix Digital conference, being held on July 13-14, 2020. IXICO will share a pre-recorded presentation by Robin Wolz, the groups SVP Science & Innovation, entitled 'Biomarkers for CNS clinical trials from imaging and actigraphy.' Two AI approaches to measure biomarkers in CNS disorders will be presented; the first approach is a method based on deep learning to segment brain volume in Huntington's disease and the second novel approach is the sleep assessment in Parkinson's disease from wrist-worn actigraphy. There will be an opportunity to set up one-to-one tele-meetings with potential customers and investors.

(), a leading provider of IT solutions to the global life sciences market, has said it intends to host a live presentation via the Investor Meet Company platform in the coming weeks. A date and time will be announced in due course. Investors can sign up to Investor Meet Company for free via https://investormeetcompany.com/instem-plc/register-investor.

Read more from the original source:

MelodyVR rises on Live Nation partnership for virtual reality gigs - Proactive Investors UK